Tag: PBMs
We head into another critical week before August recess. What’s Left of the Administration’s Prescription Drug Pricing Proposals? Last week was a difficult week for the Administration regarding its drug pricing agenda. First...
This Week’s Dose: Lots of movement in Congress ahead of the Fourth of July recess with the House and Senate both advancing a number of health care bills. President Trump also signed an execut...
This Week’s Dose: We saw a flurry of activity this week related to drug pricing, surprise billing, cost containment and tobacco as lawmakers worked through their to-do list ahead of the Memor...
This Week’s Dose: Drug pricing remains in the spotlight, but lawmakers also introduced legislation focused on surprise billing and coinsurance. Congress<...
This Week’s Dose: Another busy week for prescription drug pricing. Two more hearings took place on the subject, and a handful of bills passed out of the House. Now we watch the Senate to see ...
This Week’s Dose: Drug pricing continues to be the focus in Congress with multiple hearings and markups on the subject. So far, lowering drug prices remains a rare area of consensus among law...
This Week’s Dose: Health care continues to dominate much of the attention on Capitol Hill. Lots of hearings. New coverage expansion legislation. And more state action on Medicaid.
This Week’s Diagnosis: Recess usually means a light week. This one is no different.
Congress
PBMs Will Get Their Day…Just a We...
This Week’s Diagnosis: Congress gets busy. Pharmaceutical CEOs testify and emerge unscathed. The Administration is quiet.
Congress
M+ Check-Up: March 22, 2019
M+ Check-Up: March 1, 2019
